Cattoni Alessandro, Chiaraluce Sofia, Gasperini Serena, Molinari Silvia, Biondi Andrea, Rovelli Attilio, Parini Rossella
Department of Pediatrics, Università degli Studi di Milano Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Azienda Ospedaliera San Gerardo, Monza, (MB), Italy.
TIGET Institute, IRCCS San Raffaele Hospital, Segrate, (MI), Italy.
Mol Genet Metab Rep. 2021 Aug 9;28:100787. doi: 10.1016/j.ymgmr.2021.100787. eCollection 2021 Sep.
The impact of hematopoietic stem cell transplantation (HSCT) on growth in patients diagnosed with mucopolysaccharidosis I Hurler (MPS-IH) has been historically regarded as unsatisfactory. Nevertheless, the growth patterns recorded in transplanted patients have always been compared to those of healthy children. The objective of this study was to verify the impact of HSCT on MPS-IH long term growth achievements. The auxological data of 15 patients were assessed longitudinally and compared both to the WHO growth centiles for healthy individuals and to recently published curves of untreated MPS-IH children. Despite a progressive decrease after HSCT when estimated with reference to the WHO growth charts, median height SDS showed a progressive and statistically significant increase when comparing the stature recorded at each timepoint in our population to the curves of untreated MPS-IH individuals (from -0.39 SDS at t to +1.35 SDS 5 years after HSCT, and to +3.67 SDS at the age of 9 years, ). In conclusion, though not efficient enough to restore a normal growth pattern in MPS-IH patients, we hereby demonstrate that HSCT positively affects growth and provides transplanted patients with a remarkable height gain compared to untreated gender- and age- matched individuals.
造血干细胞移植(HSCT)对被诊断为黏多糖贮积症I型Hurler综合征(MPS-IH)患者生长的影响,在历史上一直被认为是不尽人意的。然而,移植患者记录的生长模式一直是与健康儿童的生长模式相比较。本研究的目的是验证HSCT对MPS-IH长期生长成果的影响。对15例患者的体格学数据进行纵向评估,并与健康个体的世界卫生组织生长百分位数以及最近发表的未经治疗的MPS-IH儿童的生长曲线进行比较。尽管根据世界卫生组织生长图表估计,HSCT后身高呈逐渐下降趋势,但将我们研究人群中每个时间点记录的身高与未经治疗的MPS-IH个体的曲线进行比较时,身高标准差中位数显示出逐渐且具有统计学意义的增加(从移植时的-0.39 SDS增加到HSCT后5年的+1.35 SDS,9岁时增加到+3.67 SDS)。总之,虽然HSCT在恢复MPS-IH患者正常生长模式方面效率不够高,但我们在此证明,与未经治疗的性别和年龄匹配个体相比,HSCT对生长有积极影响,并为移植患者带来显著的身高增长。